Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings
By Colin Kellaher
Applied Therapeutics shares rose sharply and hit a new 52-week high on Wednesday after the clinical-stage biopharmaceutical company reported a pair of regulatory advances for its lead product candidate.
Shares of the New York company were recently changing hands at $3.98, up 9.2%, after touching a 52-week high of $4.42 earlier in the session.
Applied said it filed last month for U.S. Food and Drug Administration approval of govorestat for the treatment of classic galactosemia, a rare genetic metabolic disease for which there is currently no available treatment.
The company also said the European Medicines Agency has validated and accepted for review its application seeking approval of the drug in the European Union.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths